Literature DB >> 16105762

Meningeal lymphomatosis as the first manifestation of splenic marginal zone lymphoma.

Jordi Bruna1, Sergio Martínez-Yelamos, Esther Alonso, Vicente Romagosa, Jordi Arruga, Jordi Arruga, Alicia Domingo, Iñigo Rojas-Marcos, Josep Petit, Francisco Rubio.   

Abstract

Meningeal lymphomatosis (ML) as the first manifestation of a splenic marginal zone lymphoma (SMZL) is rare. The descriptions of only 2 cases with this complication, one of which had ML as the first manifestation, have been published to date. We describe a 53-year-old man, an ex-smoker, who presented with transitory episodes of bilateral loss of visual acuity. On examination, only papilledema and splenomegalia were observed. The hemogram showed a predominance of lymphocytes with a villous morphology. Cytochemical staining and an immunophenotypic analysis revealed a positive reaction to tartrate-sensitive acid phosphatase and B-lineage markers (CD19+, CD20+, CD79b+, surface immunoglobulin 3 expression, immunoglobulin D+, CD5-, CD23-, CD10-, CD25-, CD103-, and CD11c-). Magnetic resonance imaging of the brain showed tumoral infiltration in both optic nerves and in the cervicodorsal meninges. The cerebrospinal fluid examination revealed significant pleocytosis, and all lymphocytes had a phenotype identical to that of the peripheral blood, confirming the presence of ML. The bone marrow section also showed lymphocytes with an immunophenotype identical to that of the peripheral blood.A splenectomy confirmed the SMZL diagnosis. Treatment with corticosteroids and intrathecal chemotherapy was administrated; however, the response was not good, and the patient died. In this report, we discuss the other 2 cases and ML in B-cell chronic lymphoproliferative disorders.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16105762     DOI: 10.1532/IJH97.E0501

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  25 in total

Review 1.  Splenic marginal zone lymphoma.

Authors:  Vito Franco; Ada Maria Florena; Emilio Iannitto
Journal:  Blood       Date:  2002-11-21       Impact factor: 22.113

2.  ICAM-1, VCAM-1, and MAdCAM-1 are expressed on choroid plexus epithelium but not endothelium and mediate binding of lymphocytes in vitro.

Authors:  B J Steffen; G Breier; E C Butcher; M Schulz; B Engelhardt
Journal:  Am J Pathol       Date:  1996-06       Impact factor: 4.307

Review 3.  Leukemic leptomeningeal involvement in stage 0 and stage 1 chronic lymphocytic leukemia.

Authors:  W G Brick; M Majmundar; L K Hendricks; A M Kallab; R E Burgess; A P Jillella
Journal:  Leuk Lymphoma       Date:  2002-01

4.  Neurolymphomatosis.

Authors:  Joachim M Baehring; Denise Damek; Emily C Martin; Rebecca A Betensky; Fred H Hochberg
Journal:  Neuro Oncol       Date:  2003-04       Impact factor: 12.300

5.  Chronic lymphocytic leukemia: study of cell subsets in cerebrospinal fluid and peripheral blood.

Authors:  M Półtorak; A Członkowska; K Nowicka
Journal:  Eur Neurol       Date:  1983       Impact factor: 1.710

6.  Spontaneous (pathological) splenic rupture in a blastic variant of mantle cell lymphoma: a case report and literature review.

Authors:  Matthew A Lunning; Maryalice Stetler-Stevenson; Peter T Silberstein; Vincent Zenger; Gerald E Marti
Journal:  Clin Lymphoma       Date:  2002-09

Review 7.  Leukemic meningitis complicating early stage chronic lymphocytic leukemia.

Authors:  K Miller; H Budke; A Orazi
Journal:  Arch Pathol Lab Med       Date:  1997-05       Impact factor: 5.534

8.  Adhesion molecule expression on B-cell chronic lymphocytic leukemia cells: malignant cell phenotypes define distinct disease subsets.

Authors:  G De Rossi; D Zarcone; F Mauro; G Cerruti; C Tenca; A Puccetti; F Mandelli; C E Grossi
Journal:  Blood       Date:  1993-05-15       Impact factor: 22.113

Review 9.  Neurologic complications of leukemia.

Authors:  Alexis Demopoulos; Lisa M DeAngelis
Journal:  Curr Opin Neurol       Date:  2002-12       Impact factor: 5.710

Review 10.  Leptomeningeal involvement in a patient with splenic lymphoma with villous lymphocytes.

Authors:  Vladimir Gotlib; Sanjay Singareddy; Usam Gergis; John Vakios; Elizabeth Guevara; Amy Chadburn; Leonid L Yavorkovsky; Arun Patel; Ahmar Butt; Asha Nayak
Journal:  Leuk Lymphoma       Date:  2002-06
View more
  2 in total

1.  A patient with splenic marginal zone lymphoma presenting with spastic paraplegia as the initial symptom.

Authors:  Yuko Wada; Yo Nishimura; Kimio Hashimoto
Journal:  Case Rep Neurol       Date:  2011-01-29

2.  Treatment of splenic marginal zone lymphoma of the CNS with high-dose therapy and allogeneic stem cell transplantation.

Authors:  Christoph Busemann; Andrej Gudzuhn; Carsten Hirt; Michael Kirsch; Silke Vogelgesang; Christian A Schmidt; Gottfried Dölken; William H Krüger
Journal:  Exp Hematol Oncol       Date:  2012-10-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.